BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17350840)

  • 1. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
    Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
    Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
    Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzopyran sulfonamides as KV1.5 potassium channel blockers.
    Lloyd J; Atwal KS; Finlay HJ; Nyman M; Huynh T; Bhandaru R; Kover A; Schmidt J; Vaccaro W; Conder ML; Jenkins-West T; Levesque P
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3271-5. PubMed ID: 17462888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
    Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
    Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.
    Lloyd J; Finlay HJ; Vacarro W; Hyunh T; Kover A; Bhandaru R; Yan L; Atwal K; Conder ML; Jenkins-West T; Shi H; Huang C; Li D; Sun H; Levesque P
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1436-9. PubMed ID: 20097068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
    Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
    Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
    Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
    Peukert S; Brendel J; Pirard B; Strübing C; Kleemann HW; Böhme T; Hemmerle H
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2823-7. PubMed ID: 15125940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
    Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
    J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
    Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia.
    Blass BE; Fensome A; Trybulski E; Magolda R; Gardell SJ; Liu K; Samuel M; Feingold I; Huselton C; Jackson CM; Djandjighian L; Ho D; Hennan J; Janusz JM
    J Med Chem; 2009 Nov; 52(21):6531-4. PubMed ID: 19888755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
    Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
    J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors.
    Zhao L; Yang Q; Tang Y; You Q; Guo X
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):462-471. PubMed ID: 35012386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the binding modes of Kv1.5 potassium channel and blockers.
    Yang Q; Du L; Wang X; Li M; You Q
    J Mol Graph Model; 2008 Sep; 27(2):178-87. PubMed ID: 18485768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudosaccharin amines as potent and selective KV1.5 blockers.
    Lloyd J; Finlay HJ; Kover A; Johnson J; Pi Z; Jiang J; Neels J; Cavallaro C; Wexler R; Conder ML; Shi H; Li D; Sun H; Chimalakonda A; Huang C; Salvati M; Levesque P
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4983-4986. PubMed ID: 25801931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers.
    Wu S; Fluxe A; Janusz JM; Sheffer JB; Browning G; Blass B; Cobum K; Hedges R; Murawsky M; Fang B; Fadayel GM; Hare M; Djandjighian L
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5859-63. PubMed ID: 16942874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors.
    Guo X; Yang Q; Xu J; Zhang L; Chu H; Yu P; Zhu Y; Wei J; Chen W; Zhang Y; Zhang X; Sun H; Tang Y; You Q
    Bioorg Med Chem; 2013 Nov; 21(21):6466-76. PubMed ID: 24071446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
    Johnson JA; Xu N; Jeon Y; Finlay HJ; Kover A; Conder ML; Sun H; Li D; Levesque P; Hsueh MM; Harper TW; Wexler RR; Lloyd J
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3018-22. PubMed ID: 24881565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening and electrophysiological evaluation of new chemotypes of K(v)1.5 channel blockers.
    Yang Q; Fedida D; Xu H; Wang B; Du L; Wang X; Li M; You Q
    ChemMedChem; 2010 Aug; 5(8):1353-8. PubMed ID: 20540065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.